LEADS BIOLABS-B (09887) announced on December 15, 2025, that the company has submitted filing materials to the China Securities Regulatory Commission (CSRC) for the proposed implementation of H share full circulation. The plan involves converting a total of 44.3916 million unlisted shares (representing approximately 22.32% of the company's total issued share capital of 199 million shares as of the announcement date) into H shares.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments